Imagen de Portada

Glucagon‐like peptide‐1 receptor agonists and the risk of nonarteritic anterior ischaemic optic neuropathy: A systematic review and meta‐analysis of observational studies

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Ronald M. Goldenberg, Ronnie Aronson, Jill Trinacty
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Diabetes, Obesity and Metabolism
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
por: Iskandar Idris
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonists and mental health: A meta‐analysis of randomized controlled trials
por: Giovanni Antonio Silverii, et al.
Publicado: (2024)

Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
por: Muhammad Aaqib Shamim, et al.
Publicado: (2024)

Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
por: Dario Giugliano, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists lower risk of cardiovascular and non‐cardiovascular mortality: A meta‐analysis of eleven cardiovascular outcome trials
por: Yu Mi Kang, et al.
Publicado: (2025)

Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
por: Robert L. Dubin, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta‐analysis and meta‐regression
por: Frederick Berro Rivera, et al.
Publicado: (2024)

Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis
por: Amanda R. Purcell, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
por: Lucas A. Mavromatis, et al.
Publicado: (2025)

GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study
por: Helen Tesfaye, et al.
Publicado: (2025)

Concerns regarding “ GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes”
por: Chien‐Hsiang Weng, et al.
Publicado: (2025)

Risk of thyroid cancer related to glucagon‐like peptide‐1 receptor agonists: A systematic review with meta‐analysis of harms of randomized controlled trials
por: Lucas Duchemin, et al.
Publicado: (2025)

Glucagon‐like peptide 1 ( GLP ‐1) receptor agonists' use during pregnancy: Safety data from regulatory clinical trials
por: Claire H. Parker, et al.
Publicado: (2025)

Continuous glucose monitoring in noninsulin‐treated type 2 diabetes: A critical review of reported trials with an updated systematic review and meta‐analysis of randomised controlled trials
por: Ronnie Aronson, et al.
Publicado: (2025)

Comparative efficacy and safety of Glucagon‐like pepetide‐1 receptor agonists with metformin in Asian versus non‐Asian patients with type 2 diabetes: A systematic review and meta‐analysis
por: Wenxuan Li, et al.
Publicado: (2025)

Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
por: Andy Bowe, et al.
Publicado: (2025)

The effect of glucagon‐like peptide‐1 receptor agonists on cardiac function and structure in patients with or without type 2 diabetes mellitus: An updated systematic review and meta‐analysis
por: Yu Zhang, et al.
Publicado: (2024)

Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists
por: David C. Klonoff, et al.
Publicado: (2024)

Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
por: Ruoyang Jiao, et al.
Publicado: (2024)

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?
por: Darren Lau, et al.
Publicado: (2024)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
por: Tae Hyeon Kim, et al.
Publicado: (2024)

A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
por: Filip K. Knop, et al.
Publicado: (2024)

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis
por: Conner E. Johnson, et al.
Publicado: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
por: Iskandar Idris
Publicado: (2024)

Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5
por: Tina Vilsbøll, et al.
Publicado: (2025)

GLP ‐1 receptor agonists for treating obesity without diabetes: A systematic review and meta‐analysis of economic evaluations
por: Teerapon Dhippayom, et al.
Publicado: (2025)

Getting the measure of the pressure: Optimal assessment of the effects of glucagon‐like peptide‐1 receptor agonists on blood pressure
por: Karen L. Jones, et al.
Publicado: (2024)

Trends in obesity and glucagon‐like peptide‐1 receptor agonist prescriptions in type 1 diabetes in the United States
por: Yunwen Xu, et al.
Publicado: (2025)

Unintentional periconceptional exposure to glucagon‐like peptide‐1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan
por: Yi‐Chang Chou, et al.
Publicado: (2025)

Sex differences in the efficacy of GLP ‐1 receptor agonists: A systematic review and meta‐analysis of cardiovascular and renal outcome trials
por: Hasan Fareed Siddiqui, et al.
Publicado: (2025)

Effects of GLP ‐1 receptor agonists on incidence and outcomes of ischemic stroke and myocardial infarction: A systematic review and meta‐analysis
por: Nawal Alammari, et al.
Publicado: (2025)

Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
por: Fu‐Shun Yen, et al.
Publicado: (2025)

Comparative effectiveness of continuous positive airway pressure and glucagon‐like peptide‐1 receptor agonists in obstructive sleep apnea: A network meta‐analysis of randomised trials
por: Gaspar R. Chiappa, et al.
Publicado: (2026)

Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
por: Masashi Hasebe, et al.
Publicado: (2025)

The effect of GLP ‐1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: A systematic review and meta‐analysis
por: Yifan Ren, et al.
Publicado: (2025)

Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence
por: Brianna Sa, et al.
Publicado: (2025)

Orforglipron, an oral non‐peptide glucagon‐like peptide‐1 receptor agonist, improves markers of β‐cell function and insulin sensitivity in type 2 diabetes
por: Julio Rosenstock, et al.
Publicado: (2025)

Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
por: Chia‐Ming Lin, et al.
Publicado: (2025)

Use of continuous glucose monitoring when initiating glucagon‐like peptide ‐ 1 receptor agonist therapy in insulin‐treated diabetes
por: Irl B. Hirsch, et al.
Publicado: (2024)

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery
por: Jason M. Samuels, et al.
Publicado: (2024)